 |
 |
On Sun 14 Dec, Ronald F. Vetter wrote: > Brian wrote in part: > > Some of the words were from the 52-page supplement 10, An algorithm for the > Management of Parkinson's Disease, December 1994 volume 44 of Neurology, > Official Journal of the American Academy of Neurology, pages S16 and S17 > section on dopamine agonists. references 46 through 55 of the supplement > edited by Doctors Koller, Silver and Lieberman pertain to agonist usage. I do > not have copies of any of those. > > NPF Parkinson Report vol XVIII issue II was mostly devoted to "Up and Coming > Medical Therapies for Parkinson's Disease" with this being the title of the > lead cover article by Matthias Kurth,MD,PhD; and the second article by > Profesor Peter Jenner, London. > > I recommend perusal of both these references - plus; keep a cynical peristence > to have the data verified - and know that knowledge regarding any science or > practice is subject to revision by learning more. > > Do not let yourself ingest more than the minimum number of these interactive > chemicals. levodopa is the natural chemical precursor to dopamine; and none of > the agonists do exactly the same processes. morphine and apomorphine have > their uses and their problems. dopamine-receptor sites are involved with our > movement and most of the emotional networks as well. take care. best wishes to > all of us. > -- > Ron Vetter 1936, '84 PD dz 'paradise is where you make it, not a place to go' janet > [log in to unmask] > http://www.ridgecrest.ca.us/~rfvetter > > > Hello Janet and Ron. Thanks to janet, I have now read the large e-mail version of an article by Dr Koller. However, I cannot see anything in that report which attempts to apportion merit points between the various dopamine agonists - indeed, back in 1994, as the subject report makes clear, there were only 2 horses in the race (Bromocriptine and Permax.). I also had a chuckle at the references to avoiding early introduction of levodopa, and the total lack of understanding of what goes on to produce increased sensitivity to levodopa. Still, it is dated 1994 - is this what you mean about checking the date of articles to make sure that they are up to date? I know that you quoted that report as a source of references, but we don't seem to have them. In any case, they must pre-date the Koller report, so I would be very wary of the provenance of those references. Incidentally, let's try to stick to the essential point that I am trying to get across which is: In PRACTICE, the experience so far (such as it is) seems to indicate that all the agonists are much the same in their ability to make-up for missing dopamine, and avoid earlier onset of diskinesias. Regards, -- Brian Collins <[log in to unmask]>